UNTERNEHMENSDATEN
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; N …
KURSVERLAUF
1T
-0,8 %
1W
-11,6 %
1M
-8,8 %
6M
+15,1 %
YTD
+49,2 %
1J
+93,2 %
2J
+244,3 %
5J
-43,8 %
10J
–
FRAG DIE AGENTEN ZU PSNL
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
9,00 $
KONSENS
14,63 $
MEDIAN
16,25 $
KURSZIEL HOCH
17,00 $
0
STRONG BUY
9
BUY
3
HOLD
0
SELL
0
STRONG SELL
12
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 20.07.2026 | BTIG | Buy | maintain |
| 20.07.2026 | Lake Street | Buy → Hold | downgrade |
| 20.07.2026 | Needham | Buy → Hold | downgrade |
| 17.07.2026 | Needham | Buy | maintain |
| 09.07.2026 | Morgan Stanley | Equal Weight | maintain |
| 12.05.2026 | Morgan Stanley | Equal Weight | maintain |
| 11.05.2026 | BTIG | Buy | maintain |
| 05.03.2026 | Morgan Stanley | Equal Weight | maintain |
KENNZAHLEN
KGV
-11,65
KBV
4,86
EV/EBITDA
-14,42
EIGENKAPITALRENDITE
-11,8 %
NETTOMARGE
-194,1 %
VERSCHULDUNG (D/E)
0,15
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
60,4 %
AKTIEN IM STREUBESITZ
64.492.488
Ø TAGESVOLUMEN (30T)
4.978.925
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| Sound Income Strategies, LLC | 0 | -200 | 30.06.2026 |
| Berbice Capital Management LLC | 0 | -100 | 30.06.2026 |
| Opal Wealth Advisors, LLC | 0 | -3.500 | 30.06.2026 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 0 | -3.900 | 30.06.2026 |
| Merck & Co., Inc. | 14.044.943 | +0 | 31.03.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.